Roche

Roche

Global pharmaceuticals and diagnostics company

People & Culture Business Partner - Diagnostics Global Operations

Full-Time
$104.6k - $194.2k/yr

+ Annual bonus

Senior
Bachelor's
Indianapolis, IN, USA
In Person

On-site in Indianapolis; relocation benefits are not available.

About the job

Requirements
  • A bachelor's degree in Human Resources, Management, or a related field, or equivalent practical experience.
  • At least 5 years of progressive human resources or related business experience, with project management and analytical problem-solving capabilities.
  • Strong understanding of human resources operational frameworks, employment laws, and compliance regulations.
  • Business fluency in English.
  • Ability to lead with Vision, Architect, Catalyst, and Coach principles and cultivate trust and psychological safety across diverse teams.
  • Ability to navigate matrixed People & Culture systems and chapters, diagnose business needs, support global initiatives, and drive courageous, authentic conversations at all levels.
  • Ability to leverage digital tools and data-driven insights for decision-making, collaboration, and alignment with strategic objectives.
  • Customer-relations capability and strong written and verbal communication skills to build long-term partnerships.
Responsibilities
  • Act as a Network Business Partner across the global footprint and collaborate across the Plan, Source, Make, Supply value chain to harmonize people practices and drive operational excellence.
  • Translate People & Culture strategies into actionable, scalable initiatives that support organizational health, performance, and a diverse, inclusive culture across multiple leadership areas.
  • Partner with the Diagnostics Global Operations People & Culture Enabling Team to co-create and drive the functional agenda across the Global Operations footprint.
  • Bridge site-level execution and the strategic People & Culture roadmap, incorporating local insights into global enabling initiatives and integrating site-specific needs into the broader global strategy.
  • Turn business insights into tailored People & Culture strategies and drive implementation through change initiatives, people streams, Work Product Teams, and squads.
  • Advance organizational design and effectiveness by driving shifts in mindset, behaviors, and agile ways of working.
  • Enhance future talent and capabilities and secure a diverse pipeline for long-term organizational goals.
  • Support initiatives or squads in other parts of the business based on shifting global priorities.
  • Align People & Culture strategy, goals, and objectives with overall business strategies.
  • Provide guidance on talent management, workforce strategies, organization design, and reward and recognition topics.
  • Recommend business-practice improvements that leverage human capital and drive organizational value.
  • Act as a coach and partner to foster VACC leadership and align culture with Roche's framework.
  • Translate business vision into actionable initiatives and lead or support Work Product Teams and squads for delivery.
  • Address retention, engagement, and leadership challenges through targeted interventions.
  • Gather and analyze internal and external data to inform decisions.
  • Diagnose root causes of work-environment issues and shape solutions with stakeholders.
  • Share insights and recommend innovative People & Culture solutions to support strategic direction.
Desired Qualifications
  • Additional language skills, such as German.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% at constant exchange rates; core profit rose 10%.
  • FDA cleared Elecsys pTau217 on August 24, 2026, unlocking Alzheimer testing at scale.
  • Tam-Peli’s 54% death-risk reduction and global phase III plans strengthen oncology growth.

What critics are saying

  • Biocon’s Perjeta biosimilar lawsuit in New Jersey threatens Herceptin-like erosion by 2027.
  • Genentech disclosed 2026 layoffs, signaling ongoing restructuring and stalled internal productivity.
  • Swiss franc strength cut H1 2026 reported sales 2%, pressuring earnings translation again.

What makes Roche unique

  • Roche’s 4,500 US cobas instruments make Elecsys pTau217 instantly scalable.
  • Roche pairs pharmaceuticals and diagnostics, creating bundled disease franchises competitors cannot match.
  • Genentech gives Roche deep biologics R&D and patented oncology manufacturing depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Yahoo Finance
Sep 1st, 2026
Roche commits $75M upfront in blood cancer deal worth up to $1.53B

Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.

Yahoo Finance
Aug 24th, 2026
Roche and Eli Lilly win FDA clearance for Alzheimer's blood test for over-55s

Roche and Eli Lilly have received FDA clearance for a blood test that helps detect signs of Alzheimer's disease in people aged 55 and older experiencing cognitive decline. The Elecsys pTau217 test measures a blood biomarker to determine whether patients are likely to have brain changes associated with Alzheimer's. The test can be performed using more than 4,500 Roche laboratory analysers already installed across the United States. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, expanding access nationwide. Pricing has not been disclosed. The clearance follows European approval in May. Blood-based testing could provide a simpler alternative to existing methods like PET imaging and cerebrospinal fluid analysis, which can be expensive and invasive.